Therapeutic Neuromodulation Systems Announces: FDA Clears the Morph Device and Grants Indication for Use as an Aid for Opioid Withdrawal

On May 2nd, 2018, the US Food and Drug Administration (FDA) granted a 510(k) clearance for the Morph Device, with an indication for use as an aid in the treatment of opioid withdrawal. The announcement was made by Therapeutic Neuromodulation Systems, LLC, a US-based sales and marketing organization with a mission to encourage and increase treatment participation by removing the fear and pain associated with opioid withdrawal.

The Morph Device is a percutaneous nerve field stimulatory system (PNFS), designed to promote mobility and ensure the comfort of patients. The device’s auricular neurostimulator produces […]

Therapeutic Neuromodulation Systems, LLC, a U.S. based sales and marketing organization for the Morph Device, announces the US Food and Drug Administration (FDA) has approved its wearable device for the treatment of opioid withdrawal symptoms. The Morph Device is a percutaneous nerve stimulator for substance use disorders.